Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death

Dori C. Woods, Han Ken Liu, Yoshihiro Nishi, Toshihiko Yanase, A. L. Johnson

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Human granulosa tumor cell (GCT) lines (KGN and COV434) were utilized to establish the combinatorial effects of TRAIL treatment and a proteasome inhibitor on cell viability, in vitro. TRAIL induced a slight, but consistent, decrease in viability for both cell lines, and pharmacologic inhibition of proteasome activity, using Z-LLF-CHO (Z-LLF), synergistically enhanced TRAIL-induced loss of viability. This enhanced sensitization was associated with the up-regulation of a TRAIL receptor, DR5, and pro-apoptotic Bax. Targeted reduction of p53 expression revealed that the ability of Z-LLF to enhance DR5 and Bax expression occurs independent of p53 activity. These studies underscore the potential to develop targeted treatments for GCTs using established cell lines.

Original languageEnglish (US)
Pages (from-to)20-27
Number of pages8
JournalCancer Letters
Volume260
Issue number1-2
DOIs
StatePublished - Feb 18 2008

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death'. Together they form a unique fingerprint.

  • Cite this